Information is the brand new oil. It’s a phrase that common readers will acknowledge, however we will’t take credit score for coining it. The credit score really goes to a British information scientist named Clive Humby. In fact, it took a advertising man to level out that uncooked oil should be become a product like gasoline or plastic to have actual worth. Equally, information should be refined – structured and analyzed – to be beneficial. Whereas some have argued that the oil-data analogy is imperfect at greatest – oil is finite, whereas information shouldn’t be, for instance – it’s nonetheless a helpful mind-set about how massive information fuels various kinds of enterprise analytics. To essentially stretch the metaphor, let’s discuss IQVIA (IQV), which might be the world’s largest provider and refinery of healthcare information to the pharmaceutical and biotech industries.
A Main Digital Healthcare Inventory
IQVIA is the results of a 2016 merger between Quintiles, a contract analysis group, and IMS Well being, a healthcare information and analytics supplier. We briefly profiled the Durham, North Carolina-based firm final month whereas reviewing a brand new digital well being ETF from notable rising tech investor Lux Capital. IQVIA is now the biggest holding in First Belief Nasdaq Lux Digital Well being Options ETF (EKG), sporting a market cap of about $40 billion, with annual income of practically $14 billion in 2021. As we identified in that article, digital well being startups are hoovering up cash, together with a record-breaking $57.2 billion in funding in 2021, up 79% from 2020 totals, in keeping with the large brains at CB Insights. Many of those corporations leverage massive information and synthetic intelligence to digitize every thing from hospital operations to scientific trials.
Large Information = Large Market
It’s the latter the place IQVIA is the heavyweight champion. Its big-data analytics assist drive scientific trial growth in assist of 85% of the world’s pharmaceutical corporations. That features designing the scientific trials, figuring out websites, and recruiting sufferers. It additionally makes use of that information to trace merchandise in 93 markets, providing advertising and consulting companies.
Let’s check out a few of the numbers that make IQVIA a pacesetter in its sector:
- The corporate boasts “one of many largest and most complete collections of healthcare data on the earth. It consists of 1.2 billion “complete, longitudinal, non-identified affected person data spanning gross sales, prescription and promotional information, medical claims, digital medical data, genomics, and social media.” So, we’re speaking a few large database of each structured and unstructured information that you would feed to algorithms all day lengthy to uncover insights about therapeutic merchandise (ie, pharmaceutical medication), scientific trial R&D, and rather more.
- IQVIA “touches” one other 100 billion healthcare data yearly.
- Its information platform holds 56 petabytes of proprietary information sourced from roughly 150,000 information suppliers and masking over a million information feeds globally.
That huge sea of information could make a giant splash when it comes to each well-explored waters and blue ocean markets. (BTW: That’s a brand new Nanalyze document for essentially the most water metaphors in a single sentence.) IQVIA estimates a total addressable market (TAM) in all probability north of $285 billion. This isn’t some random quantity that you simply discover in your typical flashy SPAC investor deck. IQVIA produces its personal market analysis and studies, in addition to operates one thing it calls the IQVIA Institute for Human Information Science.
The corporate breaks down its potential minimize of the TAM into three core sectors that it serves.
- Outsourced R&D: Biopharmaceutical spending on drug growth totaled roughly $150 billion in 2021. Greater than half of that cash, $81 billion, funneled into scientific growth, with about half of that quantity, or $39 billion, outsourced to corporations like IQVIA.
- Real-world evidence (RWE) and linked well being: The previous is an estimated $20 billion market. RWE is outlined as real-world information primarily based on sources aside from scientific trials – like the data contained in these 1.2 billion long-term data – that gives assist for or towards the advantages or dangers of a drug. Related well being, at $40 billion, consists of areas similar to “income cycle administration, payer analytics, and scientific decision-support companies.”
- Know-how-enabled business operations: That is the $75 billion kitchen sink market that captures every thing from information warehousing and software program functions to gross sales and advertising to affected person engagement and model communication.
Primarily based on 2021 income of $13.9 billion in income, IQVIA owns lower than 5% of the out there TAM. Let’s look a bit extra intently at the place these revenues come from.
The place Does IQVIA Get Its Revenues?
It will be nice if the corporate breaks down its revenues the identical means it dissects its market alternatives. Alas, that’s not the case, leaving us to offer you one other checklist of three bullet factors (breaking a Nanalyze document for three-pointed bullet level lists in a single article):
- Know-how & Analytics Options. Final 12 months, this division accounted for about 40% of revenues at $5.5 billion. There’s lots bundled in right here, together with software-as-a–service (SaaS) choices, together with customer relationship management (CRM) options. The corporate additionally applies algorithms to provide varied market and analytic studies that it says are utilized by “most massive pharmaceutical corporations.” That is additionally the place it generates revenues from real-world information enterprise, which makes use of applied sciences like pure language processing to create structured information from unstructured scientific notes. One notably attention-grabbing a part of this enterprise is what the corporate calls “data choices.” These embrace a database that tracks greater than 23 million healthcare professionals in additional than 100 international locations to ensure they get the correct medicinal advertising messages.
- R&D Options. This beautiful a lot covers the corporate’s scientific analysis division (ie, the Quintiles half of the enterprise), which accounted for practically 55% of revenues final 12 months at practically $7.6 billion. It consists of decentralized scientific trials, which upstarts like Science 37 (SNCE) declare they will do higher than legacy corporations like IQVIA. To date, buyers assume in another way: SNCE inventory has misplaced practically three quarters of its values since merging with a clean test firm in October 2021.
- Contract Gross sales & Medical Options. At about 5% of 2021 revenues, this division raked in $784 million final 12 months. Income comes from serving to shoppers commercialize, promote, and market medication, amongst different companies.
That is what the above seems to be like damaged down by phase and geography from the newest quarterly report in Q1-2022, launched simply final month:
IQVIA claims to have about 10,000 shoppers in additional than 100 international locations. Final 12 months, just one massive consumer accounted for 7% of complete revenues, so buyer focus seems comparatively small.
Ought to You Purchase IQVIA Inventory?
There’s a lot to love, however no firm this massive doesn’t have its issues. The query for buyers is to grasp whether or not any of the blemishes are greater than pores and skin deep. Another bulleted checklist is so as:
- IQVIA posted fairly sturdy revenues progress of twenty-two% between 2021 and 2020, to not point out year-over-year internet revenue shot up practically 250% to $966 million. However was final 12 months the beginning of a development or an anomaly? The final couple of years income progress was nearer to 4%-7% per 12 months and internet revenue was comparatively flat between 2018 and 2020. In truth, Q1-2022 income was extra consistent with these years, rising solely 4.7%. Internet revenue, nonetheless, nonetheless jumped 53.3%, which can assist in relation to …
- … $12 billion in debt. It’s not essentially a deal killer, so long as the corporate is managing it responsibly. That’s precisely the opinion of a Merely Wall Road author who churns out awkward-sounding phrases like IQVIA “can deal with its debt as simply as Cristiano Ronaldo may rating a aim towards an beneath 14s goalkeeper.” Definitely, all of that information doesn’t come cheaply, with the corporate dedicated to spending $657 million on information acquisition in 2022.
- Any firm concerned in healthcare information as deeply as IQVIA is will ultimately discover itself deeply enmeshed in lawsuits, particularly the IMS Well being half of the enterprise that collects data like each pharmacy transaction that takes place just about all over the place on the earth. There are at the least a few ongoing lawsuits within the South Korea department of IMS Well being over affected person and physician privateness points. As well as, IQVIA has been engaged in a five-year authorized battle with competitor Veeva Techniques (VEEV), which it has accused of stealing information and launching a rival product. In flip, Veeva alleges that IQVIA is an information bully and has created a monopoly on digital healthcare information.
Nobody factor is essentially a deal killer, however taken collectively, we’d wish to proceed to watch IQVIA to see how the income progress story unfolds, in addition to how the corporate handles the continuing debt and lawsuit points. Much less risk-averse buyers may be tempted to tug the set off now, regardless, given the overall downturn on tech shares: Our easy valuation ratio of lower than 3 says the corporate isn’t overvalued, primarily based on present market cap divided by 2022 annualized revenues ($40 billion/$14.3 billion).
Our cutoff is 40, so IQVIA inventory looks as if a cut price proper now.
Conclusion
Danger-averse retail buyers are justifiably gun shy proper now, particularly in relation to tech shares. Then again, meaning there may be worth available. IQVIA inventory appears to occupy a candy spot in healthcare information and analytics which have it poised for explosive progress, however its debt burden could also be a drag. We’ll proceed to watch the corporate to see how issues play out.
Tech investing is extraordinarily dangerous. Decrease your danger with our inventory analysis, funding instruments, and portfolios, and discover out which tech shares it is best to keep away from. Grow to be a Nanalyze Premium member and discover out right this moment!
